ALFA Finder| Metric | H1 FY27 | H2 FY26 | H1 FY26 |
|---|---|---|---|
| Revenue from operations | 9.4 | 4.4 | 5.1 |
| Other income | 0.0 | 0.1 | 0.1 |
| Total income | 9.5 | 4.5 | 5.2 |
| Profit before exceptional items & tax | 0.6 | 0.2 | 0.4 |
| Profit before tax | 0.6 | 0.2 | 0.4 |
| Net profit | 0.4 | 0.1 | 0.3 |
| Operating margin | 6.3% | 4.4% | 7.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +33.30% |
|---|---|
| Net profit, quarter on quarter | +300.00% |
| Revenue, year on year | +84.30% |
| Operating profit, year on year | +100.00% |
| Operating profit, quarter on quarter | +500.00% |
BSE results filing, BSE: 544220. Figures extracted from the filing.
Clinitech Laboratory Ltd: key numbers
- Share price
- ₹30.00
- Market cap
- ₹6.85 Cr
- Revenue (annual)
- ₹9.49 Cr
- Net profit (annual)
- ₹0.42 Cr
- P/E (TTM)
- 16.4×Sector 36.2×
- Promoter holding
- 64.62%
- FII holding
- 0.32%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Clinitech Laboratory Ltd
All →Clinitech Laboratory Other Announcement
Clinitech Laboratory filed its quarterly Reg 32 IPO utilization statement for Q1 FY27. The filing confirms no deviation or variation in use of IPO proceeds of ₹578.30 Lakhs.
Clinitech Laboratory Board Meeting Date
Clinitech Laboratory intimated BSE of a board meeting on 13 November 2026 to approve unaudited half-year results and note an internal audit report. The trading window stays closed until 48 hours after the results.
Clinitech Laboratory Other Announcement
Clinitech Laboratory submitted a certificate confirming the non-applicability of SEBI Regulation 23 regarding Related Party Transactions. This is for the half-year ended September 30, 2026.
Clinitech Laboratory Promoter Reclassification
Clinitech Laboratory Ltd reclassified 12,000 shares held by Mr. Siddhesh Nayak on behalf of Kamaxi Stock Trendz from 'Public' to 'Promoter Group' category.
Clinitech Laboratory Other Announcement
Clinitech Laboratory Limited filed a Regulation 74(5) compliance certificate for the quarter ended September 30, 2026, confirming no rematerialization requests were received.
Clinitech Laboratory Annual General Meeting
Clinitech Laboratory Limited held its 16th Annual General Meeting on September 24, 2026. Shareholders transacted items including financial statement adoption and director re-appointment.